doctor with elderly man

Consensus guideline on the holistic management of patients requiring anticoagulation

2020-06-03T06:57:00+01:00By Working party–Fay Antoniou Martins Merriman Patrickson Uprichard

This guideline was developed by a multidisciplinary expert panel: Fay M et al with the support of an educational grant from Bayer plc.

Pad+stethoscope 640x426

Stable peripheral arterial disease guideline

2018-12-07T15:50:00+00:00By Working party—Begg Antoniou Fay Garnham Nuttall

This guideline was developed by a multidisciplinary expert panel: Begg A et al with the support of a grant from Bayer plc.

Pregnant women with GP AS

Stable coronary artery disease guideline

2018-12-04T12:08:00+00:00By Working party­—Fay Banerjee Begg Bostock-Cox Gordon

This guideline was developed by a multidisciplinary expert panel: Fay M et al with the support of a grant from Bayer plc.

Erythrocytes tinted SIGN Red

SIGN antithrombotics guideline

2014-11-06T00:00:00+00:00By

A clear SIGN guideline summary exploring antiplatelet and anticoagulant agents and indications for their use, including cardiac and cerebrovascular disease.

Resource hub

  • Practical guide to recording ankle brachial pressure index (ABPI)

Educational resources

Pharmacist NVAF counselling checklist_interactive PDF

Community Pharmacist Counselling Checklist for patients with NVAF initiated on Xarelto▼ (rivaroxaban)

Commissioned by Bayer plc

This checklist was developed from content provided by Bayer plc and the format was developed by Guidelines. Information intended for healthcare professionals only.
View prescribing information and adverse event reporting information

PP-XAR-GB-1859  November 2020

DVT and PE_prescribers checklist

Xarelto▼ (rivaroxaban) patient counselling checklist for HCPs—initiating, or transitioning to rivaroxaban for eligible patients with DVT or PE*

Commissioned by Bayer plc

This checklist was developed from content provided by Bayer plc and the format was developed by Guidelines. Information intended for healthcare professionals only.
View prescribing information and adverse event reporting information
*Rivaroxaban is indicated for treatment of DVT and  PE, and prevention of recurrent DVT and PE in adults.

PP-XAR-GB-1856  November 2020

Pharmacist NVAF counselling checklist_interactive PDF

Community Pharmacist Counselling Checklist for patients with NVAF initiated on Xarelto▼ (rivaroxaban)

Commissioned by Bayer plc

This checklist was developed from content provided by Bayer plc and the format was developed by Guidelines for Pharmacy. Information intended for healthcare professionals only.
View prescribing information and adverse event reporting information

PP-XAR-GB-1857  November 2020

NVAF prescribers checklist

Xarelto▼ (rivaroxaban) patient counselling checklist for HCPs—initiating, or transitioning to rivaroxaban for stroke prevention in patients with NVAF*

Commissioned by Bayer plc

This checklist was developed from content provided by Bayer plc and the format was developed by Guidelines. Information intended for healthcare professionals only.
View prescribing information and adverse event reporting information
*Rivaroxaban is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.

PP-XAR-GB-1858  November 2020

doctor with elderly man

Consensus guideline on the holistic management of patients requiring anticoagulation

By Working party–Fay Antoniou Martins Merriman Patrickson Uprichard

This guideline was developed by a multidisciplinary expert panel: Fay M et al with the support of an educational grant from Bayer plc.